Related Experiment Videos
FTY720: from bench to bedside
1University of Texas Medical School at Houston, Division of Immunology and Organ Transplantation, Houston, TX 77030, USA. barry.d.kahan@uth.tmc.edu
Transplantation Proceedings
|March 26, 2004
Summary
FTY720, a novel immunosuppressant, reduces lymphocytes and extends organ transplant survival. It offers synergistic effects with other drugs, potentially lowering toxicity and infection risks by altering lymphocyte homing patterns.
Area of Science:
- Immunology
- Pharmacology
Background:
- FTY720 is a synthetic immunosuppressant derived from Isaria sinclairii.
- It induces lymphocytopenia and prolongs allograft survival in preclinical models.
Purpose of the Study:
- To investigate the synergistic interactions of FTY720 with other immunosuppressants.
- To elucidate the mechanism of action of FTY720 in altering lymphocyte homing patterns.
Main Methods:
- Experimental studies in animals and nonhuman primates.
- Analysis of drug interactions with calcineurin antagonists and proliferation signal inhibitors.
- Investigation of FTY720 phosphorylation and interaction with sphingosine-1-phosphate receptors.
Main Results:
- FTY720 demonstrated dose-dependent lymphocytopenia and allograft survival prolongation.
- Synergistic interactions were observed with calcineurin antagonists and proliferation signal inhibitors.
- FTY720 appears to prevent lymphocyte emigration from peripheral blood, altering homing patterns.
Conclusions:
- FTY720 represents a new class of immunosuppressants targeting lymphocyte homing.
- Its synergistic properties may allow for reduced dosages and toxicity of existing immunosuppressive therapies.
- FTY720 may offer a favorable safety profile by sparing host resistance, potentially reducing infection complications.